Literature DB >> 21818767

Successful treatment with recombinant soluble thrombomodulin of two cases of sinusoidal obstructive syndrome/hepatic veno-occlusive disease after bone marrow transplantation.

Chikako Ohwada1, Masahiro Takeuchi, Takeharu Kawaguchi, Shokichi Tsukamoto, Shio Sakai, Yusuke Takeda, Daijiro Abe, Emiko Sakaida, Naomi Shimizu, Koutaro Yokote, Tohru Iseki, Chiaki Nakaseko.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21818767     DOI： 10.1002/ajh.22137

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  8 in total

1.  Effect of eculizumab and recombinant human soluble thrombomodulin combination therapy in a 7-year-old girl with atypical hemolytic uremic syndrome due to anti-factor H autoantibodies.

Authors:  Tomohiro Udagawa; Yaeko Motoyoshi; Yu Matsumura; Akira Takei; Shohei Ariji; Eisaku Ito; Motoko Chiga; Masayuki Nagasawa; Tomohiro Morio; Shuki Mizutani
Journal:  CEN Case Rep       Date:  2013-09-12

2.  Heterogeneous response to recombinant thrombomodulin by grade of sinusoidal obstructive syndrome after pediatric stem cell transplantation.

Authors:  J Inagaki; K Kurauchi; R Fukano; M Noguchi; J Okamura
Journal:  Bone Marrow Transplant       Date:  2016-07-04       Impact factor: 5.483

3.  Sinusoidal obstructive syndrome prophylaxis with recombinant human soluble thrombomodulin is feasible in gemtuzumab ozogamicin-treated patients undergoing allogeneic hematopoietic cell transplantation.

Authors:  S Yamamoto; R Matsuno; Y Sugishita; R Kaneko; N Okamoto; M Koganesawa; S Fujita; K Akiyama; D Toyama; K Isoyama
Journal:  Bone Marrow Transplant       Date:  2017-04-03       Impact factor: 5.483

Review 4.  Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies.

Authors:  Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2020-09-09       Impact factor: 2.490

5.  Soluble Thrombomodulin Attenuates Endothelial Cell Damage in Hepatic Sinusoidal Obstruction Syndrome.

Authors:  Satoshi Takada; Tomoharu Miyashita; Yasuhiko Yamamoto; Shunsuke Kanou; Seiichi Munesue; Yoshinao Ohbatake; Shinichi Nakanuma; Koichi Okamoto; Seisho Sakai; Jun Kinoshita; Isamu Makino; Keishi Nakamura; Hidehiro Tajima; Hiroyuki Takamura; Itasu Ninomiya; Sachio Fushida; Tetsuo Ohta
Journal:  In Vivo       Date:  2018 Nov-Dec       Impact factor: 2.155

Review 6.  Thrombomodulin in disseminated intravascular coagulation and other critical conditions-a multi-faceted anticoagulant protein with therapeutic potential.

Authors:  Takashi Ito; Jecko Thachil; Hidesaku Asakura; Jerrold H Levy; Toshiaki Iba
Journal:  Crit Care       Date:  2019-08-15       Impact factor: 9.097

7.  Early coagulation disorder after allogeneic stem cell transplantation is a strong prognostic factor for transplantation-related mortality, and intervention with recombinant human thrombomodulin improves the outcome: a single-center experience.

Authors:  Masayuki Nagasawa; Teppei Ohkawa; Akifumi Endo; Noriko Mitsuiki; Toshiaki Ono; Yuki Aoki; Takeshi Isoda; Daisuke Tomizawa; Masatoshi Takagi; Michiko Kajiwara; Tomohiro Morio; Shuki Mizutani
Journal:  Int J Hematol       Date:  2013-10-01       Impact factor: 2.319

8.  Cytoprotective and pro-angiogenic functions of thrombomodulin are preserved in the C loop of the fifth epidermal growth factor-like domain.

Authors:  Xiangmin Wang; Bin Pan; Goichi Honda; Xintao Wang; Yuko Hashimoto; Hiroshi Ohkawara; Kailin Xu; Lingyu Zeng; Takayuki Ikezoe
Journal:  Haematologica       Date:  2018-06-14       Impact factor: 9.941
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.